10x Genomics (TXG) Expected to Announce Earnings on Thursday

10x Genomics (NASDAQ:TXG) will likely be releasing its Q1 2026 results after the market closes on Thursday, May 7th. Analysts expect 10x Genomics to post earnings of ($0.27) per share and revenue of $146.3810 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Thursday, May 7, 2026 at 4:30 PM ET.

10x Genomics (NASDAQ:TXG) last released its earnings results on Thursday, February 12th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.06. 10x Genomics had a negative return on equity of 6.89% and a negative net margin of 6.77%.The business had revenue of $166.03 million for the quarter, compared to analyst estimates of $160.35 million. During the same quarter in the previous year, the company posted ($0.40) earnings per share. The company’s revenue for the quarter was up .6% compared to the same quarter last year. On average, analysts expect 10x Genomics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

10x Genomics Stock Up 4.2%

Shares of 10x Genomics stock traded up $0.92 during trading on Wednesday, reaching $22.93. The company’s stock had a trading volume of 494,815 shares, compared to its average volume of 2,563,193. 10x Genomics has a 12-month low of $7.72 and a 12-month high of $26.44. The company has a market capitalization of $2.93 billion, a P/E ratio of -65.28 and a beta of 2.05. The business has a 50 day moving average price of $21.38 and a 200-day moving average price of $18.81.

Insiders Place Their Bets

In other 10x Genomics news, insider Benjamin J. Hindson sold 7,826 shares of the business’s stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $18.58, for a total value of $145,407.08. Following the completion of the sale, the insider owned 424,779 shares of the company’s stock, valued at $7,892,393.82. The trade was a 1.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Adam Taich sold 8,968 shares of the stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $18.58, for a total value of $166,625.44. Following the sale, the chief financial officer owned 288,417 shares in the company, valued at approximately $5,358,787.86. This trade represents a 3.02% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 46,426 shares of company stock valued at $902,695 in the last quarter. Insiders own 8.84% of the company’s stock.

Hedge Funds Weigh In On 10x Genomics

A number of large investors have recently added to or reduced their stakes in the company. Royal Bank of Canada lifted its stake in 10x Genomics by 806.4% in the 1st quarter. Royal Bank of Canada now owns 182,836 shares of the company’s stock valued at $1,597,000 after purchasing an additional 162,665 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in 10x Genomics by 163.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 645,366 shares of the company’s stock worth $5,634,000 after buying an additional 400,430 shares during the period. Focus Partners Wealth purchased a new position in 10x Genomics in the 1st quarter worth $92,000. Legal & General Group Plc grew its holdings in 10x Genomics by 5.7% in the 2nd quarter. Legal & General Group Plc now owns 110,864 shares of the company’s stock worth $1,284,000 after acquiring an additional 5,985 shares during the last quarter. Finally, American Century Companies Inc. bought a new stake in 10x Genomics during the second quarter worth about $933,000. Institutional investors own 84.68% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on TXG shares. Citigroup upped their price objective on 10x Genomics from $18.00 to $24.00 and gave the company a “neutral” rating in a research report on Tuesday, April 7th. Barclays upped their price objective on 10x Genomics from $22.00 to $30.00 and gave the company an “overweight” rating in a research report on Tuesday, April 14th. Leerink Partners reduced their price objective on 10x Genomics from $22.00 to $20.00 and set a “market perform” rating on the stock in a research report on Tuesday, January 27th. UBS Group upped their price objective on 10x Genomics from $14.00 to $20.00 and gave the company a “neutral” rating in a research report on Friday, February 20th. Finally, TD Cowen increased their target price on 10x Genomics from $18.00 to $19.00 and gave the stock a “hold” rating in a research report on Friday, February 13th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $20.82.

About 10x Genomics

10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.